Shots:

• The approval was based on P-III (BE VIVID/ BE READY/ BE SURE) studies evaluate Bimzelx vs PBO + ustekinumab & adalimumab in 1480 patients (315 patients were from Candana at 37 study sites) with PsO
• The studies met its 1EPs & 2EPs i.e., improvement in measures of disease activity @16wk., improvements in psoriasis involving the scalp, nails, hands & feet, patients achieved superior levels of skin clearance as measured by 90% improvement in psoriasis area & severity index (PASI 90) & IGA response of clear or almost clear skin
• Additionally, clinical responses were maintained ~@1yr. & patients achieved PASI 75 @4wk. Bimzelx is an IL-17A & IL-17F inhibitor

 Ref: Newswire.Ca | Image: Twitter